LNTH SEC Filings, Earnings & Splits

Lantheus Holdings entered into a definitive agreement to sell its contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey manufacturing facility to PharmaLogic Holdings Corp. The parties will also enter a long-term supply agreement under which PharmaLogic's Agilera franchise will manufacture lutetium Lu 177 dotatate for Lantheus.

Lantheus Holdings filed its quarterly 10-Q report for the period ending September 30, 2026, providing standard financial disclosures with no single major corporate event identified.

Lantheus Holdings furnished a press release announcing its financial results for the three and nine months ended September 30, 2026. The filing is an Item 2.02 earnings release furnished under Form 8-K.

An institutional holder filed an amended Schedule 13G for Lantheus Holdings, indicating a change in passive ownership position. The filing does not disclose a control intent or activist campaign.

An institutional holder filed an amended Schedule 13G for Lantheus Holdings (LNTH), indicating a change in passive ownership position. The filing text does not disclose specific ownership percentages or share counts.

Lantheus Holdings and Curium US Holdings each received a Second Request for additional information from the FTC regarding their pending merger, extending the HSR waiting period. The companies still expect to complete the merger in the first half of 2027.

Lantheus Holdings stockholders approved the merger agreement under which Curium US Holdings LLC will acquire Lantheus through a merger, with Lantheus becoming a wholly owned subsidiary of Curium. Stockholders also approved advisory compensation for named executive officers in connection with the merger.

Lantheus Holdings disclosed supplemental proxy disclosures in response to three stockholder lawsuits and sixteen demand letters alleging the definitive proxy statement omitted or misrepresented information about the pending merger with Curium US Holdings, including financial projections, Morgan Stanley's fairness analysis, and potential insider conflicts. The company denies the claims but provided additional disclosures to avoid litigation costs and allow the stockholder vote on the merger to proceed.

Lantheus Holdings and Curium US Holdings voluntarily withdrew and refiled their HSR pre-merger notification to extend the FTC review period for their pending merger, which is expected to close in the first half of 2027.